Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Identification of a subpopulation of patients with gastric cancer responsive to PARP inhibitors.
Authors
Simona Corso
University of Torino, Dept of Oncology; Candiolo Cancer Institute - FPO, IRCCS, Candiolo (Torino), Italy;
Simona Corso , Annalisa Petrelli , Sabrina Rizzolio , Filippo Pietrantonio , Sara Bellomo , Matteo Benelli , Loris De Cecco , Dario Romagnoli , Violeta Serra , Benedetta Pellegrino , Silvia Giordano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 432)
DOI
10.1200/JCO.2023.41.4_suppl.432
Abstract #
432
Poster Bd #
J16
Abstract Disclosures
Similar Posters
First Author: Emmanouil S. Saloustros
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third- or fourth-line treatment in patients with advanced gastric cancer.
First Author: Do-Youn Oh
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan